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Rates of neural tube defects have decreased since folic acid fortification of the food supply in the United States.
The authors’ objective was to evaluate the associations between neural tube defects and maternal folic acid intake
among pregnancies conceived after fortification. This is a multicenter, case-control study that uses data from the
National Birth Defects Prevention Study, 1998–2003. Logistic regression was used to compute crude and adjusted
odds ratios between cases and controls assessing maternal periconceptional use of folic acid and intake of dietary
folic acid. Among 180 anencephalic cases, 385 spina bifida cases, and 3, 963 controls, 21.1%, 25.2%, and 26.1%,
respectively, reported periconceptional use of folic acid supplements. Periconceptional supplement use did not
reduce the risk of having a pregnancy affected by a neural tube defect. Maternal intake of dietary folate was not
significantly associated with neural tube defects. In this study conducted among pregnancies conceived after
mandatory folic acid fortification, the authors found little evidence of an association between neural tube defects
and maternal folic acid intake. A possible explanation is that folic acid fortification reduced the occurrence of folic
acid-sensitive neural tube defects. Further investigation is warranted to possibly identify women who remain at
increased risk of preventable neural tube defects.
folic acid; neural tube defects
Abbreviations: B3, 3 months before pregnancy; CI, confidence interval; DFE, dietary folate equivalent; OR, odds ratio; P1, first
month of pregnancy.
Editor’s note: An invited commentary on this article ap-
pears on page 18, and the authors’ response is published on
page 22.
After 3 decades of epidemiologic research reporting an
association between neural tube defects and maternal use of
folic acid (1–10), public health organizations developed rec-
ommendations and supported interventions to increase folic
acid intake among women of reproductive age. In 1992, the
US Public Health Service recommended that all women of
childbearing age who are capable of becoming pregnant
should consume 400 lg of folic acid daily (11).
In 1999, the March of Dimes, Centers for Disease Control
and Prevention, and National Council on Folic Acid
launched the National Folic Acid Educational Campaign.
The US Food and Drug Administration had mandated that
all enriched cereals and grains contain 140 lg of folic acid
per 100 g of grain by January 1998 (12). In 2005, after the
National Campaign and mandatory fortification, approxi-
mately 33% of women reported taking a daily supplement
of folic acid (13), only a modest increase from the 25%
reported in 1995 (14). However, median blood folate levels
among women of childbearing age increased from 4.8 to
13.0 ng/mL between 1994 and 2000 (15), with a more recent
study (16) reporting median blood folate levels at least 2
times the levels prior to fortification.
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To evaluate the impact of this public health intervention,
4 study groups have conducted time trend analyses among
the US population, and all have reported a decline of neural
tube defects after the introduction of mandatory folic acid
fortification (17–20). Specifically, these studies reported an
11%–20% reduction in occurrence of anencephaly and
a 21%–34% reduction in occurrence of spina bifida when
comparing pre- versus postfortification rates. Similarly, the
occurrence of anencephaly and spina bifida was observed to
reduce 38% and 53%, respectively, in Canada (21) and 46%
and 51%, respectively, in Chile (22) following folic acid
fortification.
The objective of this study was to use data from the
National Birth Defects Prevention Study to evaluate the re-
lation between neural tube defects and maternal folic acid
consumption among US women conceiving pregnancies
after folic acid fortification was in place.
MATERIALS AND METHODS
The National Birth Defects Prevention Study is the larg-
est, ongoing, birth defects case-control study in the United
States. This study began in 1997 and ascertains participants
from 10 population-based birth defects surveillance systems
(23). With a relatively large data pool currently available on
participants diagnosed with a neural tube defect and controls
unaffected by a birth defect, the National Birth Defects
Prevention Study offers a unique opportunity to further in-
vestigate the effects of folate following mandatory food
fortification.
Study population
Case and control women were participants in the National
Birth Defects Prevention Study from 1 of 10 center sites
(Arkansas, California, Georgia, Iowa, Massachusetts, New
Jersey, New York, North Carolina, Texas, or Utah). A de-
tailed description of study methods has been published else-
where (23). Case women had a pregnancy affected by
anencephaly or spina bifida that did not result from a single
gene or chromosomal abnormality. Diagnoses abstracted
from medical records of fetuses or infants were confirmed
by clinical dysmorphology after review of clinical descrip-
tions and surgical/autopsy reports. Controls were a random
sample of women from each center site who delivered a live-
born infant without a structural birth defect. All pregnancies
included in this analysis were conceived on or after July 1,
1998, 6 months following the January 1998 implementation
of mandatory folic acid fortification, and included births
occurring through December 2003. Cases and controls com-
pleted a structured maternal telephone interview in English
or Spanish. Maternal interviews were conducted from
6 weeks to 24 months after each participant’s expected date
of delivery. Participation rates for maternal interviews have
been reported at 62%, 76%, and 71% for anencephaly, spina
bifida, and controls, respectively (National Birth Defects
Prevention Study, unpublished report, 2007).
Women who had preexisting type 1 or type 2 diabetes
(10 cases, 18 controls) or who reported periconceptional
use of any folate antagonist medication (4 cases, 7 controls),
including dilantin, valproic acid, sodium valproate, carba-
mazepine, methotrexate, and trimethoprim (both the hydro-
chloride and sulfate types), were excluded. Participants
whose pregnancies resulted in multiple births (39 cases,
126 controls) and who had incomplete food frequency ques-
tionnaires (4 cases, 27 controls) or supplement use informa-
tion (22 cases, 84 controls) were also excluded from the
analysis. Of the 643 cases and 3,952 controls with postfor-
tification conceptions and who participated in the study,
565 cases and 3,691 controls met all these criteria.
Folic acid supplement use and dietary intakes
Use of a multivitamin, prenatal vitamin, or single-
component vitamin was reported by participants and mea-
sured in monthly units from 3 months before pregnancy
through the last month of pregnancy. National Birth Defects
Prevention Study investigators classified whether the spe-
cific supplement reported by each participant contained
folic acid or not. Some women reported that they began to
take multivitamins or prenatal vitamins during their first
month of pregnancy. To better distinguish those who were
exposed to folic acid supplements during the development
and closure of the neural tube (within 28 days postconcep-
tion), we classified supplement use into 3 categories.
Women who reported consistently taking any supplement
containing folic acid from 3 months before pregnancy
(B3) through the first month of pregnancy (P1) were defined
as ‘‘supplement users, B3–P1’’; those who reported initia-
tion of folic acid supplements during the first month of
pregnancy were ‘‘P1 supplement initiators’’; those who re-
ported no supplement use from 3 months before pregnancy
through the first month of pregnancy were defined as ‘‘non-
users of supplements, B3–P1.’’ Consistent use was defined
as taking supplements at least half the number of days (60
days) within the B3–P1 exposure period. Nonusers of sup-
plements were the referent group for assessing the effect of
supplement use on neural tube defect risk.
Maternal dietary intake during the year before pregnancy
was based on completion of a modified Willett Food Fre-
quency Questionnaire (58 food items) administered during
the interview (24). Intake of breakfast cereals 12 weeks
before conception was determined by additional questions.
Version 19 of the USDA [US Department of Agriculture]
National Nutrient Database was used to compute daily in-
takes of micronutrient values (25). Nutritional intake from
food supplements, for example, nutritional drinks and power
bars, was excluded from these analyses. Dietary folate in-
cludes naturally occurring folates (natural folate found in
foods) and dietary folic acid (synthetic folic acid fortified
in foods). The bioavailability of ingested natural folate,
found primarily in vegetables and dried legumes, has been
estimated at 50% of the folate amount consumed, while that
of synthetic folic acid fortified in cereal and grains is 85% of
that consumed (26). Total folate intake in the diet is ex-
pressed as dietary folate equivalents (DFEs), which account
for the varying bioavailability of folates by multiplying the
amount of dietary folic acid in fortified foods by 1.7 and
then adding the amount of natural folate in foods (27).
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The intake of dietary folates was evaluated by using
measures for folic acid, natural folate, and total folate ex-
pressed as the DFE with primary focus on dietary folic acid
as used in fortification. The 10th, 30th, and 50th percentile
cutpoints for each of these measures were established from
the distribution among controls. To determine the most ap-
propriate cutpoints, we evaluated these data by using spline
analysis to determine if any alternative cutpoint would bet-
ter identify intake differences between cases and controls
(28). No such cutpoints were identified; thus, we proceeded
with the above percentile levels. Each participant was clas-
sified into 1 of 4 progressive categories of dietary folate
intake for each of the 3 folate measures. Those consuming
an amount greater than the 50th percentile were considered
the referent group in our assessment of dietary folate intake
and neural tube defect risk.
Statistical analysis
Bivariate comparisons of maternal demographic and be-
havioral characteristics among neural tube defect cases and
controls were performed by using chi-square tests. For di-
etary folate variables, comparisons of log-transformed
means between cases and controls were conducted by using
Student t tests. Unconditional logistic regression was used to
compute crude and adjusted odds ratios and 95% confidence
intervals for the assessment of the association between neural
tube defects and supplement use and dietary folate intake.
Potential covariates considered in the multivariable mod-
els included maternal race, age, education, household in-
come, body mass index, periconceptional smoking, alcohol
use, pregnancy intention, time to interview, and center site.
Covariates remained in the final adjusted model when a 10%
or greater effect was observed in the results. Interaction was
assessed by using the likelihood ratio test. Results were
reported stratified by specific phenotype, anencephaly and
spina bifida. All data were analyzed by using SAS, version
9.1, software (SAS Institute, Inc., Cary, North Carolina).
RESULTS
Characteristics of participants
Among the 565 infants or fetuses delivered by case
women, 385 had spina bifida, 177 had anencephaly, and 3
had both defects. These 3 cases with both defects were
analyzed within the anencephaly defect group. Pregnancy
outcomes among anencephaly cases were 49 (27%) live-
births, 84 (47%) terminations, and 47 (26%) fetal deaths.
Pregnancy outcomes among spina bifida cases were 337
(88%) livebirths, 39 (10%) terminations, and 9 (2%) fetal
deaths. All 3,691 controls were delivered as liveborn infants.
Maternal interviews were completed within 1 year of the
expected date of delivery for 68% of anencephaly cases,
69% of spina bifida cases, and 79% of controls. All other
interviews were completed within the second year of the
expected date of delivery.
The frequencies of demographic and behavioral charac-
teristics among case women and control women are shown
in Table 1. Distributions of maternal race/ethnicity, educa-
tion, and household income were significantly different be-
tween both anencephaly and spina bifida cases and controls
(P < 0.05). Case women were more likely than controls to
be Hispanic (35.6% vs. 23.4%, respectively), less likely to
report educational levels beyond high school (49.2% vs.
57.3%), and less likely to report household incomes at or
above $50,000 (24.1% vs. 33.1%). Anencephaly cases com-
pared with controls were less likely to report smoking
(12.8% vs. 18.7%) or alcohol drinking (21.7% vs. 29.7%)
during the month before pregnancy. Women whose pregnan-
cies were affected by spina bifida reported a higher propor-
tion of body mass index in the obese range of30 (22.1% vs.
15.3%) and were less likely to report intended pregnancies
(51.2% vs. 59.3%) than control women. The distribution of
maternal age was not different between cases and controls.
Folic acid supplement use
Almost half of the women in this study reported no use of
a supplement containing folic acid from 3 months before
pregnancy through the first month of pregnancy. Nonusers
of supplements during B3–P1 composed 45.0% of anen-
cephaly cases, 48.8% of spina bifida cases, and 48.2% of
controls (P ¼ 0.68). Conversely, 21.1%, 25.2%, and 26.1%,
respectively, of these groups of women reported consistent
use of folic acid supplement during the 3 months before
pregnancy through the first month of pregnancy (B3–P1).
Daily use of folic acid supplement throughout the B3–P1
period was reported by 16.7% of anencephaly cases, 22.6%
of spina bifida cases, and 23.4% of controls. The remaining
women in each group (33.9% of anencephaly cases, 26.0%
of spina bifida cases, and 25.7% of controls) reported initi-
ation of supplement use during the first month of pregnancy.
The overall crude odds ratio was 0.9 (95% confidence
interval (CI): 0.7, 1.2) assessing use of folic acid supple-
ments relative to no use during the B3–P1 time period.
Results assessing the relation between folic acid supplement
use and neural tube defect phenotype are reported in Table
2. Case women reported similar use of folic acid supplement
during B3–P1 as control women. In a comparison of results
from nonusers of supplements, the crude odds ratio estimat-
ing the association between supplement use and anenceph-
aly was 0.9 (95% CI: 0.6, 1.3). A crude odds ratio of 1.0
(95% CI: 0.7, 1.2) was observed for the association between
supplement use and spina bifida. After adjustment for po-
tential confounders, odds ratios inclusive of 1.0 within the
confidence intervals continued to be observed for anenceph-
aly (adjusted odds ratio (OR) ¼ 1.2, 95% CI: 0.8, 1.9) and
spina bifida (adjusted OR ¼ 1.4, 95% CI: 1.0, 1.8).
Among obese women (body mass index, 30), the asso-
ciation between supplement use in B3–P1 (vs. no use) and
anencephaly was 0.5 (95% CI: 0.1, 1.7), and among non-
obese women, it was 1.3 (95% CI: 0.8, 2.1). Adjusted odds
ratios assessing B3–P1 supplement use and spina bifida were
similar among obese (adjusted OR ¼ 1.3, 95% CI: 0.7, 2.4)
and nonobese (adjusted OR ¼ 1.4, 95% CI: 1.0, 1.9) women.
When comparing those who initiated supplement use dur-
ing the first month of pregnancy with nonusers of supple-
ments, we found higher odds ratios for anencephaly, but not
spina bifida, after adjustment for covariates (adjusted
OR ¼ 1.7, 95% CI: 1.2, 2.4).
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Table 1. Maternal Demographic and Behavioral Characteristics of Neural Tube Defect Cases and Controls,








No. % No. % No. % No. %
Total 565 180 385 3,691
Maternal race/ethnicity —a — —
White, non-Hispanic 274 48.5 83 46.1 191 49.6 2,173 58.9
African American, non-Hispanic 60 10.6 18 10.0 42 10.9 431 11.7
Hispanic 201 35.6 67 37.2 134 34.8 865 23.4
Other races 29 5.1 12 6.7 17 4.4 213 5.8
Missing data 1 0.2 0 1 0.3 9 0.2
Maternal age at conception
Median age, years 26 26 26 27
<20 years 84 14.9 34 18.9 50 13.0 518 14.0
20–25 years 176 31.1 50 27.8 126 32.7 1,080 29.3
26–35 years 262 46.4 88 48.9 174 45.2 1,806 48.9
36 years 43 7.6 8 4.4 35 9.1 287 7.8
Maternal education — — —
0–11 years 117 20.7 40 22.2 77 20.0 643 17.4
High school diploma/GED 169 29.9 57 31.7 112 29.1 923 25.0
Some college/technical 155 27.4 39 21.7 116 30.1 948 25.7
Bachelor degree 100 17.7 34 18.9 66 17.1 829 22.5
Graduate degree 23 4.1 9 5.0 14 3.6 337 9.1
Missing data 1 0.2 1 0.5 0 11 0.3
Household income — — —
<$20,000 217 38.4 69 38.3 148 38.4 1,098 29.7
$20,000–49,999 169 29.9 49 27.2 120 31.2 1,151 31.2
$50,000 136 24.1 48 26.7 88 22.9 1,220 33.1
Missing data/refused 43 7.6 14 7.8 29 7.5 222 6.0
Maternal smoking, B1 —
Yes, smoked 89 15.8 23 12.8 66 17.1 692 18.7
No 476 84.2 157 87.2 319 82.9 2,999 81.3
Maternal alcohol drinking, B1 —
Yes, drank alcohol 146 25.8 39 21.7 107 27.8 1,096 29.7
No 416 73.6 141 78.3 275 71.4 2,580 69.9
Missing data 3 0.5 0 3 0.8 15 0.4
Maternal body mass index, kg/m2 — —
Median values 24.4 23.3 24.8 23.5
<18.5 23 4.1 10 5.6 13 3.4 219 5.9
18.5–<25 276 48.8 97 53.9 179 46.5 1,962 53.2
25–<30 119 21.1 36 20.0 83 21.5 788 21.3
30 111 19.7 26 14.4 85 22.1 563 15.3
Missing data/out of range 36 6.4 11 6.1 25 6.5 159 4.3
Intended pregnancy — —
Yes, stopped contraception/
wanted to be pregnant then
300 53.1 103 57.2 197 51.2 2,189 59.3
No, all others 265 46.9 77 42.8 188 48.8 1,502 40.7
Abbreviations: B1, month before pregnancy; GED, general equivalency diploma.
a —, statistically different distribution from controls (P < 0.05). All participants with missing values were excluded
from statistical comparisons.
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Race- and ethnicity-specific patterns of folic acid supple-
ment use are reported in Table 3. Among controls, 35.6% of
non-Hispanic white women compared with 63.3% of non-
Hispanic black women (P < 0.05) and 71.3% of Hispanic
women (P < 0.05) reported no use of supplement from
3 months before pregnancy through the first month of preg-
nancy. Only 7.2% of Hispanic controls and 14.9% of non-
Hispanic black controls reported use of a supplement from
B3 through P1, compared with 36.3% for non-Hispanic
white controls.
For non-Hispanic white women, crude odds ratios for
B3–P1 supplement use were 1.2 (95% CI: 0.7, 2.1) when
comparing anencephaly cases and 1.3 (95% CI: 0.9, 1.9)
when comparing spina bifida cases with controls. Non-
Hispanic blacks had odds ratios for B3–P1 supplement use
at 2.8 (95% CI: 0.8, 10.4) for anencephaly and 1.2 (95% CI:
0.5, 2.8) for spina bifida, while odds ratios among Hispanics
were 0.7 (95% CI: 0.2, 2.2) for anencephaly and 0.4 (95%
CI: 0.2, 1.2) for spina bifida. Supplement use–race interac-
tions were not significant for anencephaly (P ¼ 0.57) or
spina bifida (P ¼ 0.08). Counts among non-Hispanic black
and Hispanic populations were relatively small; thus, inter-
pretation of these data is limited.
Dietary folic acid intake
The 10th, 30th, 50th, and 90th percentile values for
dietary folic acid, natural folate, and folate DFE among
Table 2. Association of Maternal Folic Acid Supplement Use and Neural Tube Defects,


















Nonusers, B3–P1 81 1,778 Referent Referent Referent Referent
Users, B3–P1 38 965 0.9 0.6, 1.3 1.2 0.8, 1.9
P1 initiator 61 948 1.4 1.0, 2.0 1.7 1.2, 2.4
Spina bifida
Nonusers, B3–P1 188 1,778 Referent Referent Referent Referent
Users, B3–P1 97 965 1.0 0.7, 1.2 1.4 1.0, 1.8
P1 initiator 100 948 1.0 0.8, 1.3 1.1 0.9, 1.5
Abbreviations: B3, 3 months before pregnancy; P1, first month of pregnancy.
a The adjusted anencephaly model includes the covariates maternal race and education.
b The adjusted spina bifida model includes the covariates maternal race, body mass index, and
pregnancy intent.
Table 3. Association of Maternal Folic Acid Supplement Use and Specific Neural Tube Defects Stratified by Race/Ethnicity, National Birth
Defects Prevention Study, 1998–2003
Controls Anencephaly Spina Bifida















Nonusers, B3–P1 773 35.6 24 28.9 Referent Referent 59 30.9 Referent Referent
Users, B3–P1 789 36.3 30 36.1 1.2 0.7, 2.1 79 41.3 1.3 0.9, 1.9
P1 initiator 611 28.1 29 34.9 1.5 0.9, 2.6 53 27.8 1.1 0.8, 1.7
Black, non-Hispanic
Nonusers, B3–P1 273 63.3 6 33.3 Referent Referent 28 66.7 Referent Referent
Users, B3–P1 64 14.9 4 22.2 2.8 0.8, 10.4 8 19.0 1.2 0.5, 2.8
P1 initiator 94 21.8 8 44.4 3.9 1.3, 11.5 6 14.3 0.6 0.3, 1.6
Hispanic
Nonusers, B3–P1 617 71.3 45 67.2 Referent Referent 93 69.4 Referent Referent
Users, B3–P1 62 7.2 3 4.5 0.7 0.2, 2.2 4 3.0 0.4 0.2, 1.2
P1 initiator 186 21.5 19 28.4 1.4 0.8, 2.5 37 27.6 1.3 0.9, 2.0
Abbreviations: B3, 3 months before pregnancy; P1, first month of pregnancy.
Neural Tube Defects and Maternal Folate Intake 13
Am J Epidemiol 2009;169:9–17
anencephaly cases, spina bifida cases, and controls are re-
ported in Table 4. Comparison of log-transformed means of
these 3 dietary intake measures among each case population
and controls found statistically significant differences only
among women whose pregnancies were affected by anen-
cephaly. Specifically, women who had pregnancies affected
by anencephaly reported a lower mean intake of dietary
folic acid and total folate DFE than did women whose preg-
nancies were unaffected by a birth defect (P < 0.05).
Log-transformed means for dietary folic acid intake were
statistically higher among non-Hispanic black and Hispanic
controls compared with non-Hispanic white controls
(P < 0.05). Median values for dietary folic acid were
129.2 lg for non-Hispanic white controls, 145.5 lg for
non-Hispanic black controls, and 152.8 lg for Hispanic con-
trols. Statistically significant differences in dietary folic acid
were not observed among the racial/ethnicity groups among
either anencephaly or spina bifida cases.
The odds ratios measuring the association between die-
tary folic acid and anencephaly and spina bifida stratified by
supplement use are presented in Table 5. Among those who
did not use supplements, women who had pregnancies af-
fected by anencephaly or spina bifida were no more likely to
report consuming dietary folic acid levels in the lowest 50th
percentile of intake than were controls. Odds ratios measur-
ing the association between either anencephaly or spina
bifida and the 10th, 11th–30th, or 31st–50th percentile
groups of dietary folic acid intake, using those in the >50th
percentile as the referent group, did not present a consistent
pattern providing evidence of either a positive or a negative
association. Thus, women not using supplements with af-
fected pregnancies were no more likely to report being in
the lower 50th percentile of dietary folic acid intake than
controls who were not taking supplements. A similar finding
was observed for women who used supplements consistently
between the third month prior to pregnancy and the first
month of pregnancy and for those who reported initiating
supplement use in the first month of pregnancy.
For women who reported initiating supplement use in the
first month of pregnancy, an adjusted odds ratio of 2.5 (95%
CI: 1.3, 4.6) was observed when anencephalic case women
were compared with control women for the 11th–30th per-
centile of dietary folic acid intake relative to the >50th
percentile intake level. However, for those below the 11th
percentile of dietary folic acid intake, an adjusted odds ratio
of 1.7 (95% CI: 0.7, 4.2) was observed. When spina bifida
cases were compared with controls for initiation of supple-
ment use in P1, all odds ratios were less than 1.0, and con-
fidence intervals were inclusive of 1.0.
Results similar to those presented in Table 5 using dietary
folic acid were observed when natural folate and total folate
expressed as DFE were used to assess the risk of neural
tube defects (data not shown). Given concerns that preg-
nancy outcomes among cases may impact our findings,
we repeated the analyses including participants from only
the 5 surveillance programs (Arkansas, California, Iowa,
Georgia, and Texas) that have consistently included elec-
tively terminated fetuses and stillbirths throughout the study
Table 4. Descriptive Percentile Values for Dietary Folate DFE, Folic Acid, and Natural Folate









Dietary folic acid, lg —a
10th percentile 39.3 33.3 41.3 38.1
30th percentile 75.5 67.2 77.4 87.0
50th percentile 125.3 108.7 138.7 136.1
90th percentile 392.2 335.0 404.1 368.7
Dietary folate DFE, lg DFE —
10th percentile 218.2 207.9 219.6 229.3
30th percentile 342.4 320.1 359.1 349.3
50th percentile 462.1 413.7 478 468.6
90th percentile 964.1 891.3 1,013.2 977.9
Dietary natural folate, lg
10th percentile 106.9 108.5 105.0 108.3
30th percentile 164.8 160.7 166.8 165.0
50th percentile 218.3 204.8 228.2 213.0
90th percentile 454.2 432.7 466.5 416.5
Abbreviation: DFE, dietary folate equivalent.
a —, t tests comparing log-transformed means of dietary folate DFE and dietary folic acid
between anencephaly cases and controls statistically significant (P < 0.05). All other t test com-
parisons between cases and controls were not statistically significant.
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period. Results were similar to those reported here (data not
shown).
DISCUSSION
Among US women who were enrolled in the National
Birth Defects Prevention Study and conceived after folic
acid fortification, we found insufficient evidence for an as-
sociation between maternal folic acid supplement use or
dietary folate intake and neural tube defect occurrence.
Reported folic acid supplement use was similar among
women who had neural tube defect-affected pregnancies
and women who had pregnancies not affected by birth de-
fects. Furthermore, after stratification for supplement use,
there was no consistent evidence to support an association
between dietary folic acid intake and occurrence of anen-
cephaly or spina bifida. These findings, therefore, are not
consistent with the larger body of evidence reported from
Table 5. Association Between Anencephaly or Spina Bifida and Dietary Folic Acid Intake Stratified by Supplement

















No supplement use B3–P1
10th folic acid intake 9 193 1.2 0.6, 2.6 1.2 0.6, 2.6
11th–30th folic acid intake 19 332 1.5 0.9, 2.7 1.7 0.9, 3.0
31st–50th folic acid intake 19 342 1.5 0.8, 2.6 1.5 0.8, 2.7
>50th folic acid intake 34 911 Referent Referent Referent Referent
Supplement users B3–P1
10th folic acid intake 5 85 1.4 0.5, 4.0 1.5 0.5, 4.0
11th–30th folic acid intake 6 208 0.7 0.3, 1.8 0.7 0.3, 1.8
31st–50th folic acid intake 8 204 1.0 0.4, 2.2 1.0 0.4, 2.3
>50th folic acid intake 19 468 Referent Referent Referent Referent
Supplement users, P1 initiators
10th folic acid intake 7 92 1.7 0.7, 4.1 1.7 0.7, 4.2
11th–30th folic acid intake 22 198 2.5 1.3, 4.6 2.5 1.4, 4.8
31st–50th folic acid intake 11 193 1.3 0.6, 2.7 1.3 0.6, 2.8
>50th folic acid intake 21 465 Referent Referent Referent Referent
Spina bifida
No supplement use B3–P1
10th folic acid intake 12 193 0.6 0.3, 1.1 0.5 0.3, 1.1
11th–30th folic acid intake 53 332 1.5 1.0, 2.1 1.5 1.0, 2.2
31st–50th folic acid intake 26 342 0.7 0.5, 1.1 0.7 0.4, 1.1
>50th folic acid intake 97 911 Referent Referent Referent Referent
Supplement users B3–B1
10th folic acid intake 13 85 1.8 0.9, 3.6 1.8 0.9, 3.5
11th–30th folic acid intake 29 208 1.7 1.0, 2.8 1.7 1.0, 2.8
31st–50th folic acid intake 16 204 0.9 0.5, 1.7 0.9 0.5, 1.7
>50th folic acid intake 39 468 Referent Referent Referent Referent
Supplement users, P1 initiators
10th folic acid intake 7 92 0.6 0.3, 1.4 0.7 0.3, 1.5
11th–30th folic acid intake 16 198 0.6 0.4, 1.2 0.7 0.4, 1.2
31st–50th folic acid intake 19 193 0.8 0.5, 1.4 0.8 0.4, 1.4
>50th folic acid intake 58 465 Referent Referent Referent Referent
Abbreviations: B3, 3 months before pregnancy; P1, first month of pregnancy.
a Dietary folic acid supplement use stratifications by percentile.
b Adjusted anencephaly models include maternal race and education.
c Adjusted spina bifida models include maternal race, maternal body mass index, and pregnancy intent.
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periods prior to fortification reporting a protective effect of
supplement use on neural tube defect risk, including 2 dif-
ferent randomized controlled trials (5, 6), 3 nonrandomized
trials (1, 2, 10), and 5 observational studies (3, 4, 7–9). In
1989, Mills et al. (29) reported no association between neu-
ral tube defect occurrence and folic acid supplement use,
and Shaw et al. (8) reported in 1995 no association among
higher educated women.
We postulate several hypotheses that may explain our
findings. First, it is possible that we failed to find an asso-
ciation because of a ‘‘ceiling effect.’’ Folate intake among
the US childbearing population may have reached levels
where nearly all folate-sensitive neural tube defects have
been prevented. Two reports from the National Health and
Nutrition Examination Survey (NHANES) indicated that,
following mandatory folic acid fortification, serum levels
of folate in US women of reproductive age were 2–4 times
higher than levels prior to fortification (15, 16). Another
study from the National Health and Nutrition Examination
Survey used 24-hour recall data and reported that US
women of reproductive age had increased their median total
folate intake by at least 100 lg/day since fortification, al-
though the magnitude of these increases varied by race/
ethnicity (30). Ecologic studies have reported declining oc-
currence of neural tube defects in the United States and
other countries since folic acid fortification (17–22). We
speculate that most women in the National Birth Defects
Prevention Study may have had sufficient folic acid intake
to protect their fetuses from having folate-responsive neural
tube defects.
Second, our findings may be explained by potential bias.
Our results relied on maternal recall of supplement use and
dietary intake. By classifying the exposure period for sup-
plement use as consistent use versus no use, we hoped to
minimize this potential bias. Nevertheless, errors in report-
ing are possible and may be differential with respect to
neural tube defect-affected offspring. Various versions of
the food frequency tool used in this study had been validated
in other studies (24, 31, 32), but we acknowledge the in-
herent limitation of this tool to measure intakes in our pop-
ulation. Other dietary assessment methods, such as 24-hour
recalls or food diaries, were not feasible with this study
design. To further evaluate potential selection bias, we an-
alyzed data from the 5 sites where all pregnancy outcomes
have been consistently monitored and found results (data
not shown) similar to those reported for all sites.
Third, although the National Birth Defects Prevention
Study is the largest case-control study of birth defects to
be conducted in the United States, the number of affected
cases included in our analyses may be insufficient to detect
a true difference, particularly if the magnitude of the true
difference is small. Small sample sizes prevented us from
further exploring subgroup analyses, particularly potential
racial/ethnic differences. In light of the evidence showing
a smaller decline in the occurrence of neural tube defects
since fortification among Hispanic compared with non-
Hispanic white pregnancies (19), race and ethnic differences
should be further evaluated.
Finally, our study estimated risks for the dietary intake of
folic acid but not tissue-dose levels. Effects of genetic var-
iation and the interactive relation with other micronutrients
and neural tube defects should be considered for more com-
prehensive etiologic assessments. The National Birth
Defects Prevention Study is an ongoing study and will
provide an opportunity for continued evaluation of the as-
sociation between neural tube defects and maternal micro-
nutrient intake.
Despite these limitations, collaborative efforts of the
National Birth Defects Prevention Study resulted in the ac-
crual of a relatively large population of study participants.
We recommend further studies evaluating the effects of sup-
plement use in the postfortification era. Research is war-
ranted to identify additional independent risk and
protective factors for neural tube defects, with efforts made
to identify women who may require higher levels of folic
acid or alteration of other modifiable factors.
ACKNOWLEDGMENTS
Author affiliations: Department of Pediatrics, University
of Arkansas for Medical Sciences and Arkansas Children’s
Hospital Research Institute, Little Rock, Arkansas (Bridget
S. Mosley, Mario A. Cleves, Charlotte A. Hobbs); Depart-
ments of Epidemiology and Nutrition, University of North
Carolina School of Public Health, Chapel Hill, North Car-
olina (Anna Maria Siega-Riz); March of Dimes Foundation,
California Research Division, Oakland, California (Gary M.
Shaw); Birth Defects Epidemiology and Surveillance
Branch, Texas Department of State Health Services, Austin,
Texas (Mark A. Canfield); School of Public Health, Univer-
sity of Texas Houston Science Center, Houston, Texas
(D. Kim Waller); and Slone Epidemiology Center at Boston
University, Boston, Massachusetts (Martha M. Werler).
This work was supported by funds from the Centers for
Disease Control and Prevention (grant U50/DD613236).
The authors thank the panelists convened by the Centers
for Disease Control and Prevention in August 2007 for their
expertise and advice on this project. Panelists included
Drs. Lynn Bailey, Dave Erickson, Richard Johnston, Joel
Kimmons, Jim Mills, Godfrey Oakley, Irwin Rosenberg,
Mary Serdula, Dixie Snider, and Stein Emil Volset. The
authors would also like to thank the birth defects researchers
at the Centers for Disease Control and Prevention for their
support and input on this project. Nutrient values for the
National Birth Defects Prevention Study were computed
by the Nutrition Epidemiology Core at the University of
North Carolina-Chapel Hill.
The contents are solely the responsibility of the authors
and do not necessarily represent the official views of the
Centers for Disease Control and Prevention.
Conflict of interest: none declared.
REFERENCES
1. Laurence KM, James N, Miller M, et al. Increased risk of
recurrence of pregnancies complicated by fetal neural tube
16 Mosley et al.
Am J Epidemiol 2009;169:9–17
defects in mothers receiving poor diets, and possible benefit of
dietary counselling. Br Med J. 1980;281(6255):1592–1594.
2. Smithells RW, Nevin NC, Seller MJ, et al. Further experience
of vitamin supplementation for prevention of neural tube de-
fect recurrences. Lancet. 1983;1(8332):1027–1031.
3. Mulinare J, Cordero JF, Erickson JD, et al. Periconceptional
use of multivitamins and the occurrence of neural tube defects.
JAMA. 1988;260(21):3141–3145.
4. Milunsky A, Jick H, Jick S, et al. Multivitamin/folic acid
supplementation in early pregnancy reduces the prevalence of
neural tube defects. JAMA. 1989;262(20):2847–2852.
5. Prevention of neural tube defects: results of the Medical
Research Council Vitamin Study. MRC Vitamin Study
Research Group. Lancet. 1991;338(8760):131–137.
6. Czeizel AE, Dudás I. Prevention of the first occurrence of
neural tube defects by periconceptional vitamin supplemen-
tation. N Engl J Med. 1992;327(26):1832–1835.
7. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic
acid exposure and risk of occurrent neural tube defects. JAMA.
1993;269(10):1257–1261.
8. Shaw GM, Schaffer D, Velie EM, et al. Periconceptional vi-
tamin use, dietary folate, and the occurrence of neural tube
defects. Epidemiology. 1995;6(3):219–226.
9. Khoury MJ, Shaw GM, Moore CA, et al. Does periconceptional
multivitamin use reduce the risk of neural tube defects associ-
ated with other birth defects? Data from two population-based
case-control studies. Am J Med Genet. 1996;61(1):30–36.
10. Berry RJ, Li Z, Erickson J, et al. Prevention of neural-tube
defects with folic acid in China. China-U.S. Collaborative
Project for Neural Tube Defect Prevention. N Engl J Med.
1999;341(20):1485–1490.
11. Recommendations for the use of folic acid to reduce the
number of cases of spina bifida and other neural tube defects.
MMWR Morb Mortal Wkly Rep. 1992;41(RR-14):1–7.
12. Food and Drug Administration. Food standards: amendment of
standards of identity for enriched grain products to require
addition of folic acid. Fed Regist. 1996;61:8781–8797.
13. Use of dietary supplements containing folic acid among
women of childbearing age—United States, 2005. MMWR
Morb Mortal Wkly Rep. 2005;54(38):955–958.
14. Knowledge and use of folic acid by women of childbearing
age—United States, 1995. MMWR Morb Mortal Wkly Rep.
1995;44(38):716–718.
15. Folate status in women of childbearing age, by race/
ethnicity—United States, 1999–2000. MMWR Morb Mortal
Wkly Rep. 2002;51(36):808–810.
16. Pfeiffer CM, Johnson CL, Jain RB, et al. Trends in blood folate
and vitamin B-12 concentrations in the United States, 1988–
2004. Am J Clin Nutr. 2007;86(3):718–727.
17. Honein MA, Paulozzi LJ, Mathews TJ, et al. Impact of folic
acid fortification of the US food supply on the occurrence of
neural tube defects. JAMA. 2001;285(23):2981–2986.
18. Williams LJ, Mai CT, Edmonds LD, et al. Prevalence of spina
bifida and anencephaly during the transition to mandatory folic
acid fortification in the United States. Teratology. 2002;66(1):
33–39.
19. Canfield MA, Collins JS, Botto LD, et al. Changes in the birth
prevalence of selected birth defects after grain fortification
with folic acid in the United States: findings from a multi-state
population-based study. Birth Defects Res A Clin Mol Teratol.
2005;73(10):679–689.
20. Robbins JM, Tilford JM, Bird TM, et al. Hospitalizations of
newborns with folate-sensitive defects before and after forti-
fications of foods with folic acid. Pediatrics. 2006;118(3):
906–915.
21. De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural
tube defects after folic acid fortification in Canada. N Engl J
Med. 2007;357(2):135–142.
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